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ABSTRACT
Risperidone and its Deconstructed Analogs: Functional Effects on the
5HT2AR
By: Sneha Shah, B.A.
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
at Virginia Commonwealth University
Virginia Commonwealth University, 2015
Thesis Director: Diomedes E. Logothetis, Ph.D.
Chair, Department of Physiology and Biophysics
G protein-coupled receptors (GPCRs) are seven-transmembrane domain receptors that
sense extracellular signal and activate intracellular signaling pathways. The serotonin 5HT2A
receptor (or 2AR) is one of the GPCRs coupled to Gq proteins, activating PLC and hydrolyzing
PIP2. This hydrolysis causes a diffusion of bound PIP2 away from the channel binding site
resulting in G protein-gated inwardly rectifying K+ channel (GIRK) inhibition and a downstream
stimulation of Ca2+ release from endoplasmic reticulum stores. Previous experiments have
demonstrated that the serotonin 5HTA receptor is a target of serotonergic psychedelic drugs,
such as LSD, and partially mediates the action of many atypical antipsychotic drugs. However,
the portion responsible for the functional activity and response of these drugs is unknown. The
purpose of this study was to functionally characterize four deconstructed analogs of risperidone,
an atypical antipsychotic agent, using two assays: by application to 5HT2A receptors in Xenopus
oocytes and by calcium epifluorescence imaging in a HEK293 cell line stably expressing 2AR.
Our experiments revealed that two analogs, RHV-006 and RHV-008, are partial agonists by
themselves and greatly antagonize the effects of serotonin. RHV-006 and RHV-008 contain the
piperidine and benzisoxizole ring systems of risperidone. RHV-023 and RHV-026, on the other
hand, are more efficacious agonists than RHV-006 and RHV-008 but display a non-antagonistic
effect with serotonin. RHV-023 and RHV-026 contain both the piperidine and benzisoxizole ring
systems in addition to part of the diazabicyclo ring, thus containing more of risperidone’s
structure than RHV-006 and RHV-008.
!
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INTRODUCTION
G- Protein- Coupled Receptors (GPCRs) and their downstream signaling partners
constitute one of the largest classes of molecular targets contributing to many diseases. Half the
current drugs on the market target GPCRs, generating tens of billions of dollars in revenue and
representing a significant portion of the portfolio of many pharmaceutical companies (Solis, et
al, 2014). Approximately 80% of known hormones and neurotransmitters activate cellular signal
transduction mechanisms by activating GPCRs (Birnbaumer et al., 1990). Due to their
importance, GPCRs and their signaling have been studied extensively and breakthroughs in our
understanding of how their work has received multiple Nobel Prizes (Lin, 2013).
GPCRs are transmembrane receptors with an extracellular N terminus, a cytoplasmic C
terminus and 7 transmembrane helices connected by loops (Ballesteros and Weinstein, 1994).
GPCRs sense molecules outside the cell and activate intracellular signal transduction through
pathways involving activation of G- proteins (Lefkowitz, 2007). These heterotrimer G (G-alphabeta-gamma) proteins transduce ligand binding of the receptor to downsteam effectors. The cycle
is described in three steps. The first occurs when binding of the ligand to the GPCR induces a
conformational change to the receptor that is transduced to the Galpha subunit, such that its
affinity for intracellular GTP is greatly increased over the already bound GDP, and in a Mg2+
dependent manner GDP is exchanged with GTP. The activated GPCR is acting as a guanine
nucleotide exchange factor (GEF) to stimulate the exchange of nucleotides with the G- alpha
subunit. Second, the G-alpha subunit uses the binding energy of GTP to produce a conformation
favoring its dissociation from G-beta-gamma and association with effector proteins. Similarly,
the dissociated Gbeta-gamma can also interact with effectors. Third, the activation of G- protein
subunits ends by hydrolysis of GTP to GDP by the GTPase activity of the G-alpha subunit,
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enabling re-association with Gbeta-gamma. Following re- association, the heterotrimeric Gprotein can interact again with GPCRs and the activation cycle can continue (Solis, et al, 2014).
Co-expression of GPCRs with an inwardly rectifying potassium (Kir) channel reporter
allows for membrane-delimited G- protein signaling, and its quantification can be achieved
through measurement of ionic currents. Kir channels are named for their ability to conduct K+
ions better in the inward (Vm < Ek) rather than the outward (Vm > Ek) direction (Hibino et al.,
2010). Assessment of Gq signaling in oocytes involves co-expression of a Gq-coupled GPCR
with a channel reporter, followed by ligand-induced hydrolysis of PIP2 resulting in current
inhibition (Figure 2). Kir activity is highly dependent on interactions with PIP2 to maintain its
activity. Stimulation of the Gq coupled GPCR by the appropriate ligand leads to activation of
PLC and hydrolysis of PIP2 to inositol triphosphate (IP3) and diacylglycerol (DAG). The
decrease in PIP2 concentration in the immediate vicinity of the channel causes diffusion of
bound PIP2 away from the channel-binding site resulting in current inhibition. IP3 stimulates
Ca2+ release from endoplasmic reticulum stores, while DAG stimulates PKC that phosphorylates
many protein targets (Keselman, 2007).
The Gq-coupled GPCR used in this experiment is the 5HT2A serotonin receptor. The
5HT2 receptors are one of seven families that have been identified (5HT1-5HT7) and
subpopulations have been described for several of these. The family of 5HT2 receptors are all
GPCRs, except for 5HT3 receptors which are nonselective Na+/K+ ion channel receptors
(Glennon, 2000). The three receptor subtypes within the 5HT2 family have 70 to 80% sequence
homology, and have been found to be consistent with those of transmembrane-spanning GPCRs
coupled to a phosphoinositol second messenger system (Glennon, 2000). 5HT2A receptors are
mainly expressed in the Central Nervous System (CNS), with a distribution of these receptors at

!

2!

various densities throughout the brain. The highest density is in the neocortex, specifically in the
frontal cortex and hippocampus modulating local circuitry. Both of these brain areas are known
to be involved importantly in associative learning across a number of species and learning
paradigms (Zhang, 2013). These receptors have also received considerable attention from a
neuropsychiatric standpoint. Various antipsychotic agents and antidepressants bind with
relatively high affinity to the 5HT2A receptors. For example, chronic administration of 5HT2A
antagonist results in a paradoxical down-regulation of 5HT2A receptors; such a down- regulation
would be of benefit in the treatment of depression (Glennon, 2000). 5HT2A receptors also play a
role in anxiety, depression, schizophrenia, migraine and drug abuse. Several 5HT2A antagonists
are currently in clinical trails as potential antipsychotic agents. Compared to indolealkylamine
and classical hallucinogens (such as LSD), phenylalkylamine hallucinogens (such as DOB, DOI)
are much more 5HT2 selective (Glennon, 2002).
Risperidone is an atypical antipsychotic and an inverse agonist at 5HT2A receptors
(Marder, 1997). Inverse agonists bind to constitutively active receptors, stabilize them and shift
receptor equilibrium towards the inactive state, reducing the level of basal activity (Milligan,
2003). It is most often used to treat delusional psychosis such as schizophrenia, in addition to
some forms of bipolar disorder and psychotic depression (Glick, et al, 2001). Schizophrenia is a
devastating psychiatric disorder, having its onset in puberty and lasting throughout life (Schotte,
1996). Conventional antipsychotic agents have displayed major shortcomings in the treatment of
schizophrenia: the induction of neurological side effects (dystonia, parkinsonism, akathisia,
tardive dyskinesia) and often a lack of efficacy for the treatment of the negative symptoms of
schizophrenia (Seeman 1980; Ellenbroek 1993). Clinical studies have shown risperidone to
improve both the positive symptoms (hallucinations, delusional thinking, severe excitement and
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unusual behavior) and the negative symptoms (anergy, apathy, lack of drive, social withdrawal
and depressive mood) of schizophrenia with a low incidence of extrapyramidal side effects
(EPS) (Megens, 1994). Although both types of symptoms are independent from each other, they
may coexist in the same patient (Stevens 1973; Crow 1980; Hafner 1993). It has also shown
some success in treating symptoms of Asperger’s Syndrome and autism (Fisman, et al, 1996).
The actions of risperidone are considered before those of other 5HT2 antagonists because this
drug is the most potent and selective 5HT2A antagonist available to clinicians (Schotte, 1996;
Richelson and Souder, 2000).
Risperidone is a benzisoxazole derivative. Its molecular structure is shown in Figure 1A.
The short-term aim of this study is to examine four deconstructed analogs of risperidone to
determine the portion that is important to 5HT2AR functional activity and response. Risperidone
was deconstructed by first removing a portion of the diazabicyclo ring to afford RHV-023 and
RHV-026 (Fig. 1). The next two compounds, RHV-008 and RHV-006, solely contain the
piperidine ring and the benzisoxazole ring system (Fig. 1B). RHV-008 contains a methyl group,
derived from the carbon chain, whereas, RHV-006 does not retain the methyl group (Gaitonde,
2013).
We demonstrated that all four deconstructed analogs have a functional effect on the
5HT2A receptor. The data were collected mainly by performing two-electrode voltage clamp
recordings and epifluorescence calcium imaging.
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Figure 1. Risperidone and its deconstructed analogs along with
serotonin.
A

Diazabicyclo!ring!
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Figure 2. PIP2 signaling pathway indirectly modulates ion channels
through the activation of protein kinase C (PKC) and Ca2+
dependent enzymes using secondary messengers. Activation of
phospholipase C (PLC) results in the hydrolysis of phosphatidylinositol (PIP2) to produce
inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 activates Ca2+ channels in the
endoplasmic reticulum (ER) triggering the release of Ca2+ from intracellular stores. The
cytoplasmic rise in Ca2+ level and DAG then activate protein kinase C (PKC), which in turn
phosphorylates K+ channels, thereby modulating current across the membrane.
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MATERIALS AND METHODS
A) Electrophysiology
Xenopus laevis oocytes have been used as a heterologous expression system for studying
ion channels in a controlled cellular environment. Oocytes are enzymatically isolated, and
microinjected with 1-2 ng cRNA constructs. Oocytes are then incubated for 2 days at 18°C for
expression, as previously described (Solis, et al, 2014). The responses are analyzed
electrophysiologically using the two-electrode voltage-clamp technique. A high potassium
solution is used to record basal channel expression levels. The high potassium solution contains
96 KCl, 1 NaCl, 1 MgCl2, 5 KOH/HEPES, in mM). A 3mM BaCl2 solution is used to block
GIRK4* currents. The presence of an endogenous response is utilized as positive control for the
second messenger system coupled to the initial response being studied. In the case of Gq- GPCR,
a calcium- induced chloride spike is the endogenous response visualized as a large outward
current spike and a smaller inward current spike.

B) HEK-293 cells stably expressing 2AR
This cell line was kindly provided by Dr. Jose Miguel Eltit (Department of Physiology
and Biophysics, Virginia Commonwealth University, Richmond, VA). To produce stable
inducible cell lines using the Flp-In T- REx expression system (Invitrogen), the 2AR DNA
fragment was subcloned into the pcDNA5/FRT/TO vector to generate the
pCDNA5/FRT/2AR/FRT/TO plasmid. The inducible expressing cells were made following the
manufacturer’s protocol. Briefly, the Flp-In T-REx host cell lines are HEK cells with a single
FRT recombination site and a Tet repressor gene. The T-Rex system is a tetracycline regulated
mammalian expression system that uses regulatory elements. These cells were co- transfected
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with the pcDNA5/2AR/FRT/TO and the pOG44 plasmids. The latter encodes the Flp
recombinase. Clones that have inserted a single copy of the gene inserted into the recombination
site acquire a hdyrogmycin resistance. 2AR was induced adding doxycycline 1ug/mL to the
culture media for 3 days.

C) Cell Culture and Transient Transfection
These cells were maintained with guidance by Dr. Lia Baki (Department of Physiology
and Biophysics, Virginia Commonwealth University, Richmond, VA). The HEK293 cell line
stably expressing 5HT2AR was grown in Dulbecco’s modified Eagle’s medium (DMEM)
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) (Atlanta
Biologicals, Inc., Lawrenceville, GA) and Hygromycin- containing media. The HEK cells were
transiently transfected with 5HT2AR.

D) Calcium Imaging
The Ca2+ sensitive dye Fura2AM (Life Technologies) was dissolved in DMSO pluronic
F-127 20% and then was diluted in Imaging Solution (recipe below). The Ca2+ unbound form of
Fura2 gets excited at 380 nm and the Ca2+ bound form at 340 nm. The emitted light is measured
at around 510 nm. The fluorescence intensity increases at 340 nm with increasing Ca2+
concentration and decreases at 380 nm for the unbound form resulting in an emitted ratio
wavelength of 510 nm. For calcium imaging, load cells with Fura-2 AM (2 μM) diluted in
calcium-containing extracellular imaging solution (IS) (130 NaCl, 4 KCl, 2CaCl2, 1MgCl2, 10
Hepes, 10 glucose, pH 7.4, in mM) to get a final concentration of 5.5 μM. The cells were loaded
for 25 minutes with Fura-2AM all at 37°C. Fura-2AM is a high affinity, intracellular calcium
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indicator that is ratiometric and UV light excitable. Then the cells were washed twice with IS
and placed on the stage of an epifluorescence microscope. All the compounds used were
dissolved in IS and when high K+ solution was used in equimolar amount of NaCl it was
substituted by KCl. The setup consists of an Olympus IX70 microscope equipped with a
polychrome V (Till photonics, Gragelging, Germany) as a light source, a Luca S digital camera
(Andor Technology, Belfast, UK), and an automatic perfusion system (AutoMate Scientific,
Berkeley, CA). The imaging system was controlled by the Live Acquisition Software from Till
Photonics. The measurements were done under constant perfusion at RT (23 degC) or at 35degC
using a ThermoClamp-1 heater (AutoMate Scientific, Berkley, CA). The objective used was an
Olympus 20x 0.8NA Oil. The Fura-2 signal was acquired switching the excitation wavelength
between 340/10nm and 380/10nm at 6Hz, the dichroic mirror used was LP490 and the emission
wavelength was 510/40nm. All signals were background subtracted.

E) Statistical Analysis
All oocyte recordings were obtained using Clampfit 9.2 (Molecular Devices, Sunnyvale,
CA) and transferred to Excel software (Microsoft, Albuquerque, NM). The first few data points
of the current versus time plot were averaged to obtain the basal current. The agonist-induced
currents were obtained by averaging several current values that appear immediately after the
slope of the ramp current started to change. Similarly, the data points after barium block were
averaged. Barium-sensitive basal and agonist-induced currents were calculated by subtracting the
current remaining after barium block from basal and agonist-induced currents, determined as
described above. In the statistic analysis, basal and agonist-induced currents from each recording
were again averaged. Error bars in the figures represent standard error. The standard deviations
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for each data set were divided by the square root of the number of recordings to get the standard
errors.
All calcium imaging recordings were obtained using Live Acquisition (Innsbruck,
Austria) and transferred to Excel software (Microsoft, Albuquerque, NM). The maximum and
basal value (average value between 20 and 30 second) was taken. A threshold of 1.05 was used
over the ratio of maximum to basal, to distinguish between responsive and non- responsive cells.
In statistical analysis, the average maximum values from responsive and non-responsive cells at
each concentration of RHV-006/8 were analyzed. Total number of cells was calculated between
the two groups. Average time traces were graphed between different concentrations. Error bars
in the figures represent standard error. The standard deviations for each data set were divided by
the square root of the number of recordings to get the standard errors.
Statistical significance of experiments involving four groups was assessed by one- way
ANOVA. Statistical significance of experiments comparing two groups was assessed by
Student’s t-test.

F) Analogs
The exact chemical names for the deconstructed analogs are as follows: RHV-006 is 6fluoro-3-(piperidin-4-yl)benzisoxazole,

RHV-008

is

6-fluoro-3-(1-methyl-piperidin-4-

yl)benzisoxazole,, RHV-023 is 4-[(4-(6-fluorobenzisoxazol-3-yl)piperidin-1-yl)-1-(piperidin-1yl)]butan-1-one

and

RHV-026

is

6-fluoro-3-[(1-(4-piperidin-1-yl)butylpiperidin-4-

yl)]benzisoxazole. All compounds were submitted as their HCl salts. They were synthesized in
the laboratory. The synthesis is represented in the VAS slides and poster (Gaitonde, 2013).
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RESULTS
RHV-006 is a partial agonist and suppresses 5-HT activity on the 5HT2A receptor.
Figure 3 shows time course examples of serotonin and RHV-006 effects on GIRK currents.
Figure 3A reports currents at Vm=-80mV (negative currents) and Vm=+80mV (positive
currents). 1μM 5-HT elicited large transient calcium-activated chloride currents that showed
outward rectification. In addition, there is a 5-HT induced inhibition of the inwardly rectifying
GIRK4* current. In contrast, RHV-006 did not induce calcium-activated chloride current spikes,
but did inhibit GIRK4* currents (Figure 3B). When comparing the relative inhibition by these
ligands, 5-HT at 1µM and RHV-006 at 10 µM, the risperidone fragment elicited 34% agonism
compared to 5-HT from 10 experiments in oocytes from 3 different frogs (Figure 4). The RHV006 effects showed saturation by 0.1µM (Figure 5). Additional experiments will be necessary to
obtain a full dose-response leading to the saturated levels of the effect. When applied together
with 1µM 5-HT, 10 µM RHV-006 reduced Gq activity by ~67% (Figure 6), bringing the current
to its saturated level of partial agonism (see Figure 6). A dose-dependent response of RHV-006
inhibition of the 5-HT response is shown in Figure 7, where it can be seen that the half maximal
inhibition lies between 0.1-5 µM.

RHV-008 is also a partial agonist and suppresses 5-HT activity on the 5HT2A receptor.
Figure 8 shows current time courses for 5-HT (Figure 8A) and RHV-008 (Figure 8B). Just like,
RHV-006, RHV-008 did not induce Ca2+-activated Cl- currents. RHV-008 elicited 27% agonism
when applied alone at 10μM (Figure 9). Application of RHV-008 alone showed partial agonism
saturation by 10μM (Figure 10). Additional experiments will be required for a full dose-response
curve to determine the EC50 value for this compound. When applied together with 1µM 5-HT, 10
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µM RHV-008 reduced Gq activity by ~77% (Figure 11). Application of RHV-008 together with
1 μM 5-HT showed that the receptors became saturated by around 5 μM (Figure 12).

RHV-023 and RHV-026 are weak agonists and have an additive effect on 5-HT activity on
5HT2AR.
Application of 10μM RHV-023 and RHV-026 together with 1µM 5-HT produced partial
agonism of ~45% and ~74%, respectively (Figure 13) (data produced by Jason Younkin and
Peter Drossopoulos)).

Figure 13 compares the partial agonism of all four deconstructed

risperidone fragments. In the presence of 5-HT, RHV-023 and RHV-026 did not decrease the 5HT-mediated inhibition of K+ currents (Figure 14). In fact, RHV-026 was additive to the 5-HT
effect, suggesting that these two compounds did not compete with 5-HT to trigger their effects.

Figure 15 summarizes the effects of the deconstructed risperidone fragments on their partial
agonism and their effect on the 5-HT effects on the 5HT2AR.

Cells transfected with 2AR show a decrease in calcium signaling when RHV-006 or RHV008 is added along with 5-HT.
The addition of 1μM 5-HT to 2AR expressing HEK-293 cells using epifluorescence showed a
robust calcium signaling increase, with the Fura2 ratio (340/380nm) reaching 1.6 (Figure 16A).
However, addition of 10 μM of RHV-006 (Figure 16D) or RHV-008 (Figure 16E) alone did not
elicit a calcium signal, consistent with the experiments in oocytes where these compounds did
not elicit Ca2+-activated Cl- currents (see Figures 3B and 8B). When 10μM of RHV-006 (Figure
16B) or RHV-008 (Figure 16C) was added to 2AR cells in the presence of 1μM 5-HT, however,
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both the number of cells responding and the level of responses to 5-HT decreased. Only 28% of
all cells showed a calcium response to 10μM RHV-006 in the presence of 1μM 5-HT. 30% of all
cells showed a calcium response to 10μM RHV-008 in the presence of 1μM 5-HT (Figure 17).
Thus, a large number of cells did not show a calcium response to 1μM 5-HT in the presence of
10μM RHV-006/8. Furthermore, the level of response of the responsive cells decreased with the
addition of RHV-006/8. Addition of 10μM RHV-006 showed an approximately 65% decrease in
the Fura2 ratio calcium response (Figures 16B, 18) compared to that of 1μM 5-HT. Addition of
10μM RHV-008 showed an approximately 40% decrease in the Fura2 ratio calcium response
(Figures 16C, 18) compared to that of 1μM 5-HT. A dose response, using the addition of 7
concentrations of RHV-008 (0.01uM, 0.1μM, 0.5uM, 1μM, 5uM, 10μM, 100uM) to 1μM 5-HT,
showed a decrease of the level of response (Figures 19, 20) starting at 5 μM RHV-008. 100 μM
RHV-008 and 1 μM 5-HT showed almost no calcium response – the signal was completely
quenched at this concentration. Interestingly, the concentrations lower than 5uM showed a
kinetic change, according to their decrease in Fura2 ratio level of response over a period of time
compared to the time trace of 1μM 5-HT applied alone.
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Figure 3. Gq signaling activity of 2AR in response to serotonin and
RHV-006. Representative barium- sensitive traces of GIRK4* currents obtained in oocytes
in (A) response to 1μM serotonin (5-HT) and (B) response to 10 µM of RHV-006. Note the lack
of a calcium- induced chloride spike, visualized as a large spike in the outward current, when
RHV-006 is added, compared to an evident spike with serotonin.

A
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Figure 4. Agonism of 10μM RHV-006 on 2AR. Normalized Gq activity
(GIRK4* current inhibition) compared to basal currents of 10μM RHV-006 obtained in oocytes
expressing 2AR. Each bar is normalized to the Gq activity of 1μM 5-HT. Each bar represents
n=3 frogs and 10 oocytes each with error bars depicting the standard error of the mean.
(*** indicates 95% confidence intervals do not overlap; estimated p-value ≤ 0.001 compared to
1μM 5-HT )
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Figure 5. Saturation of RHV-006 Agonism. Summary of normalized Gq
activity (GIRK4* current inhibition) compared to basal currents obtained in oocytes expressing
2AR in response to increasing concentrations (0.01uM to 10μM) of RHV-006. By 0.1μM RHV006, saturating agonist effects have been reached; 10μM of RHV-006 does not give any larger
effect. Each bar is normalized to the Gq activity of 1μM 5-HT. Each bar represents n=1 frog and
4-5 oocytes each with error bars depicting the standard error of the mean. (*** indicates
p<0.0001 for comparison to 1μM 5-HT.

indicates p<0.05 for comparison to 0.01μM RHV-

006)
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Figure 6. Effect of 10μM RHV-006 in the presence of 5-HT on
5HT2AR. Normalized Gq activity (GIRK4* current inhibition) compared to basal currents of
10μM RHV-006 in the presence of 1μM 5-HT obtained in oocytes expressing 2AR. Each bar is
normalized to the Gq activity of 1μM 5-HT. Each bar represents n=3 frogs and 15 oocytes each
with error bars depicting the standard error of the mean. (*** indicates 95% confidence intervals
do not overlap; estimated p-value ≤ 0.001 compared to 1μM 5-HT)
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Figure 7. Inhibition Dose Response of RHV-006 in the presence of 5HT. Summary of normalized Gq activity (GIRK4* current inhibition) compared to basal
currents obtained in oocytes expressing 2AR in response to increasing concentrations (0.01uM to
10μM) of RHV-006 in the presence of 1μM 5-HT. Each bar is normalized to the Gq activity of
1μM 5-HT. (*** indicates p<0.0001 for comparison to 1μM 5-HT.

indicates p<0.0001

for comparison to 1μM 5-HT + 0.01μM RHV-006)
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Figure 8. Gq signaling activity of 2AR in response to serotonin and
RHV-008. Representative barium- sensitive traces of GIRK4* currents obtained in oocytes
in (A) response to 1μM serotonin (5-HT) and (B) response to 10 µM of RHV-008. Note the lack
of a calcium- induced chloride spike, visualized as a large spike in the outward current, when
RHV-006 is added, compared to an evident spike with serotonin.

A

!

B
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Figure 9. Agonism of 10μM RHV-008 on 5HT2AR. Normalized Gq activity
(GIRK4* current inhibition) compared to basal currents of 10μM RHV-008 obtained in oocytes
expressing 2AR. Each bar is normalized to the Gq activity of 1μM 5-HT. Each bar represents
n=3 frogs and 12 oocytes each with error bars depicting the standard error of the mean. (***
indicates 95% confidence intervals do not overlap; estimated p-value ≤ 0.001 compared to 1μM
5-HT)

!

20!

Figure 10. Saturation of RHV-008 Agonism. Summary normalized Gq activity
(GIRK4* current inhibition) compared to basal currents obtained in oocytes expressing 2AR in
response to increasing concentrations (0.1μM to 100uM) of RHV-008. By 10μM RHV-008,
saturating agonist effects have been reached; 100uM of RHV-006 does not give any larger effect.
Each bar is normalized to the Gq activity of 1μM 5-HT. (* indicates 95% confidence intervals do
not overlap; estimated p-value<0.05 compared to 1μM 5-HT)
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Figure 11. Effect of 10μM RHV-008 in the presence of 5-HT on
5HT2AR. Normalized Gq activity (GIRK4* current inhibition) compared to basal currents of
10μM RHV-008 in the presence of 1μM 5-HT obtained in oocytes expressing 2AR. Each bar is
normalized to the Gq activity of 1μM 5-HT. Each bar represents n=3 frogs and 12 oocytes each
with error bars depicting the standard error of the mean. (*** indicates 95% confidence intervals
do not overlap; estimated p-value ≤ 0.001 compared to 1μM 5-HT)
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Figure 12. Inhibition Dose Response of RHV-008 in the presence of
5-HT.

Summary of normalized Gq activity (GIRK4* current inhibition) compared to basal

currents obtained in oocytes expressing 2AR in response to increasing concentrations (0.1μM to
10μM) of RHV-008 in the presence of 1μM 5-HT. Each bar is normalized to the Gq activity of
1μM 5-HT. (*** indicates p<0.0001 for comparison to 1μM 5-HT.

indicates p<0.0001

for comparison to 1μM 5-HT + 0.1μM RHV-008)
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Figure 13. RHV Agonism Totals. Summary bar graph of the agonist- induced Gq
activity of RHV-006, RHV-008, RHV-023 and RHV-026. Each bar is normalized to the Gq
activity of 1μM 5-HT. Each bar represents n=2-3 frogs and 7-12 oocytes each with error bars
depicting the standard error of the mean. (*** indicates p<0.0001 for comparison to 1μM 5-HT.
indicates p<0.001 for comparison to 10μM RHV-008, $ indicates p<0.0.05 for
comparison to 10μM RHV-006 )
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Figure 14. Total RHV Effects in the Presence of 5-HT. Summary bar
graph of the agonist- induced Gq activity in the presence of 1μM 5-HT of RHV-006, RHV-008,
RHV-023 and RHV-026. Each bar is normalized to the Gq activity of 1μM 5-HT. Each bar
represents n=3 frogs and 12-15 oocytes each with error bars depicting the standard error of the
mean. (*** indicates p<0.0001 for comparison to 1μM 5-HT, ** indicates p<0.001 for
comparison to 1μM 5-HT, * indicates p<0.05 for comparison to 1μM 5-HT.

indicates

p<0.0001 for comparison to 10μM RHV-006 and 10μM RHV-008, $ indicates p<0.05 for
comparison to 10μM RHV-023)
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Figure 15. Summary of RHV Analogs. Summary chart of the agonist-induced Gq
activity values of RHV-006, RHV-008, RHV-023 and RHV-026 compared to 1μM 5-HT (100%
Gq activity).
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Figure 16. Calcium Signal of RHV-006 and RHV-008 by themselves
and in the Presence of 5-HT using Epifluorescence Assay. Three images
of representative time series of Fura2 fluoresence intensity (340nm/380nm) obtained in HEK
cells expressing 2AR with the addition at 30 seconds of (A) 1μM Serotonin, (B) 1μM Serotonin
and 10μM RHV-006, (C) 1μM serotonin and 10μM RHV-008. The protocol for (A), (B) and (C)
is: low potassium (30 s), compounds (45 s) and low potassium (30 s). Two images of
representative time series of Fura2 fluoresence intensity (340nm/380nm) obtained in HEK cells
expressing 2AR with the addition at 30 seconds of (D) 10μM RHV-006 and (E) 10μM RHV-008
shows no calcium response; after washing with low potassium, 1μM of serotonin is added at 85
seconds in (D) and (E). The protocol for (D) and (E) is: low potassium (30 s), compound (45 s),
1μM serotonin (30 s), low potassium (30 s). Each line depicts one cell.

A

D
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Figure 17. % Calcium Responsive Cells vs % Non- Calcium
Responsive Cells of RHV-006 and RHV-008 in the presence of 5-HT.
The bar graph summarizes the percent of calicium responsive and non- calcium responsive cells
of (A) 10μM RHV-006 in the presence of 1μM 5-HT (1 experiment in 80 cells total) and
(B)10μM RHV-008 in the presence of 1μM 5-HT (1 experiment in 94 cells total). (C) shows a
summary chart of percent values of calcium responsive and non- calcium responsive cells of both
RHV-006 and RHV-008 in the presence of 1μM 5-HT.

A

B

C
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Figure 18. Normalized Calcium Response of Responsive Cells of
RHV-006 and RHV-008 in the presence of 5-HT. Fura2 fluoresence maximal
intensities of 1μM 5-HT, the addition of 10μM RHV-006 and 10μM RHV-008 were evaluated at
30 seconds and normalized to their initial values at 0 seconds (100%). All ratios were then
normalized to the ratio of 1μM 5-HT. The protocol is low potassium (30 s), compounds (45 s)
and low potassium (30 s). Only HEK293 cells showing a calcium response were analyzed. (***
indicates 95% confidence intervals do not overlap; estimated p-value ≤ 0.001 compared to 1μM
5-HT)
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Figure 19. Average Time Traces of Responsive Cells of RHV-008 at
Various Concentrations in the Presence of 1μM 5-HT. Representative
time series of Fura2 fluoresence intensity (340nm/380nm) obtained in HEK cells expressing
2AR with the addition at 30 seconds of increasing concentrations (0.01uM to 100uM) of RHV008 in the presence of 1μM 5-HT. The protocol is low potassium (30 s), compounds (45 s) and
low potassium (30 s). Only HEK293 cells showing a calcium response were analyzed.
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Figure 20. Inhibition Dose Response of RHV-008 in the presence of
5-HT in HEK Cells. Fura2 fluoresence intensities of 1μM 5-HT and the addition of
increasing concentrations (0.01uM to 100uM) of RHV-008 were evaluated at 30 seconds and
normalized to their initial values at 0 seconds (100%). All ratios were then normalized to the
ratio of 1μM 5-HT. The protocol was as follows: 30 seconds of low potassium solution, 45
seconds of solution of interest and 30 seconds of low potassium solution. Only HEK293 cells
showing a calcium response were analyzed.
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DISCUSSION AND FUTURE DIRECTIONS
The purpose of this study was to examine four deconstructed analogs of risperidone to
determine the portion(s) of the molecule that is (are) important to 5HT2AR functional activity
and response (Figure 1). Risperidone is a novel antipsychotic that possesses advantages over
other antipsychotic agents in terms of efficacy and side effects. Ascertaining which analog
accounts for risperidone’s action was investigated in two functional assays: the two-electrodevoltage clamp (TEVC) and the Epifluorescence technique. We employed the GIRK4* channel as
a reporter of Gq-coupled GPCR signaling and used two-electrode voltage-clamp to monitor
currents. Perfusion with 1μM 5-HT caused a robust inhibition of K+ current. The spike observed
at the onset of serotonin perfusion signifies activation of the oocyte endogenous Ca2+- activated
chloride current (ICl-Ca) and provides additional evidence of the serotonin- induced PIP2
hydrolysis and IP3 mediated rise in intracellular Ca2+ (Figure 2).
The normalized Gq activation (relative to the maximal current inhibition – 100%) was
plotted as a function of serotonin concentration. Perfusion with 10μM RHV-006 (Figure 4) or
RHV-008 (Figure 9) alone showed approximately 30% normalized Gq activity using a TEVC
functional assay. Although inhibition of current was clear, we did not observe a Ca2+-activated
chloride current spike. In the TEVC assay, these deconstructed analogs were seen as partial
agonists. Interestingly, neither compound elicited a calcium signal while using Epifluoresence
microscopy (Figures 3 and 8). A possible explanation for this may due to insufficient PIP2
hydrolysis and IP3 production for Ca2+ release from endoplasmic reticulum stores. Although a
decrease in PIP2 concentration in the immediate vicinity of the channel would cause diffusion of
its bound PIP2 away from the channel binding site resulting in current inhibition and was evident
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with TEVC, there was no downstream rise in intracellular Ca2+ evident with TEVC or
Epifluorescence.
Since GIRK4* current inhibition signified Gq activation, we then proceeded to
investigate the concentrations at which RHV-006 and RHV-008 agonism showed saturation, and
plot them as a function of serotonin concentration at 1µM. Agonism with RHV-006 appears to
saturate by 0.1μM (40% normalized Gq activity) (Figure 5), while agonism with RHV-008
appears to saturate by 10μM (65% normalized Gq activity) (Figure 10). Next, we investigated
the concentrations at which the RHV-006 and RHV-008 inhibitory effects on serotonin activity
were saturated. The normalized Gq activation (relative to the maximal current inhibition – 100%)
was plotted as a function of serotonin concentration. We proceeded to perform a serotonin
inhibition dose- response experiment with RHV-006 and determine the apparent affinity of 2AR
for serotonin in the Xenopus oocyte expression system. The results of the dose- response
experiment allow us to extrapolate a likely IC50 of approximately 0.1μM (Figure 7).
(Additionally, inhibition of 2AR with RHV-008 and 1μM 5-HT seems to saturate at 5uM of
RHV-008 (Figure 12).
We then looked at both RHV-006 and RHV-008’s effects in the presence of serotonin
using calcium imaging. 10μM of RHV-006 and RHV-008 showed a significant decrease in the
number of calcium responsive cells (~20%) (Figure 17). The time traces also showed a
significant number of unresponsive cells in the presence of both RHV-006/8 and 1μM 5-HT
(Figures 16, 17). In addition, the level of response of the responding cells is also decreased.
Since a decrease in calcium signals signifies a change at binding at the receptor level, we then
proceeded to perform a serotonin inhibition dose- responsive experiment with RHV-008 in the
presence of 1μM 5-HT using the HEK293 2AR cell line. Figure 19 nicely shows the progressive
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time traces of increasing RHV-008 concentrations in the presence of 1μM 5-HT; the level of
response of these responsive cells decreased starting at 5uM RHV-008. Figure 20 shows that the
IC50 of RHV-008 in the presence of 1μM 5-HT lies between 5 and 10μM. It can also be
extrapolated that there are receptor- ligand kinetics involved between RHV-008 and serotonin
binding to 2AR over time. Specifically, the IC50 at 85 seconds is 0.5µM, a greater than 10-fold
difference from the IC50 at 30 seconds. It is conceivable that in some cases, such as in dynamic
regulation of signal transduction processes, kinetic control prevails rather than affinity control.
The data for analogs RHV-023 and RHV-026 were kindly provided by Jason Younkin
and Peter Drossopoulos. RHV-023 and RHV-026 have 45 and 74% Gq agonism respectively and
consequently seem to be more efficacious agonists than RHV-006 and RHV-008. Both RHV-023
and RHV-026 do not appear to affect serotonin’s activity; in fact, RHV-026 seems to have a nonantagonistic, additive effect on serotonin’s activity.
Our two-electrode voltage-clamp assay findings show that all four deconstructed analogs
by themselves have partial Gq activity normalized to basal. However, the Epifluorescence assay
does not show downstream calcium signaling of these compounds. This could be explained by
the greater sensitivity of the TEVC assay at the receptor- channel membrane level, and perhaps
insufficient PIP2 hydrolysis for intracellular calcium release. Next, our findings show that the
addition of 1-(piperidin-1-yl)butane (structure in analogs RHV-023 and RHV-026) (Fig. 1B) to
the piperidine ring and benzisoxazole ring system does not suppress the activity of serotonin, but
the removal of this structure greatly suppresses serotonin’s activity. Interestingly, although
RHV-006 and RHV-008 are structurally most similar to serotonin, these analogs instead act
similarly to risperidone. On the other hand, RHV-023 and RHV-026 act the least similarly to
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risperidone, but have the most structural similarity. This could be accounted for by the removal
of the amine and methyl group from the risperidone molecule.
In conclusion, the smaller compounds, RHV-006/8, are partial agonist by themselves and
antagonize the effects of serotonin down to their partial agonism level. The longer compounds,
RHV-023/26, are more efficacious agonists than RHV-006/8, but do not display an antagonistic
effect on serotonin, unlike compounds RHV-006/8.
Further research is needed to complete deconstructed analogs’ dose responses for
agonism and antagonism using the TEVC assay. Additionally, further research is needed to
complete the same dose responses using the epifluorescence assay. The combined study of these
deconstructed analogs using both assays discussed in the present work will give us a better idea
of the portion of risperidone that is important to 5HT2AR functional activity and response.
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